<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Pharmacological doses of corticoids may result in <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> but with individual sensitivity </plain></SENT>
<SENT sid="1" pm="."><plain>In paediatric <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD), <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> are needed in the majority of the patients but there are less studies related to tapering off the drugs </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to estimate the frequency of <z:hpo ids='HP_0000846'>adrenal insufficiency</z:hpo> in children with IBD that were at the end of their systemic <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> therapy course </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The study was a retrospective case series of 59 consecutive paediatric IBD patients (median age 14.1 years; <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> n = 22, <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> n = 26, unclassified <z:hpo ids='HP_0002583'>colitis</z:hpo> n = 11) that were on oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi> therapy about to be discontinued </plain></SENT>
<SENT sid="4" pm="."><plain>The study patients were treated in a tertiary university hospital setting </plain></SENT>
<SENT sid="5" pm="."><plain>Serum morning <z:chebi fb="1" ids="17650">cortisol</z:chebi> was measured with Immulite 2000 cortisol kit </plain></SENT>
<SENT sid="6" pm="."><plain>Values &lt; 20 nmol/l are undetectable and indicate <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e>, values &gt; 69 nmol/l are considered to represent <z:mpath ids='MPATH_458'>normal</z:mpath> basal secretion </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The morning <z:chebi fb="1" ids="17650">cortisol</z:chebi> was below the reference range in 20% of the patients and undetectable in 10% </plain></SENT>
<SENT sid="8" pm="."><plain>Low <z:chebi fb="1" ids="17650">cortisol</z:chebi> levels associated with higher daily <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> doses (median 7.2 mg/m(2) vs. 3.0 mg/m(2) in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="1" ids="17650">cortisol</z:chebi> levels, p &lt; 0.05) and with the long duration of the treatment (median 11 months vs. 4 months, p &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with undetectable <z:chebi fb="1" ids="17650">cortisol</z:chebi> levels recovered within few weeks (median 5.6 weeks) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In paediatric IBD prolonged courses of <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> are frequent due to the steroid-dependent nature of the disease in a considerable proportion of patients </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">Adrenal suppression</z:e> may occur in at least one fifth of the patients despite slowly tapering off the <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Notably, this is based on a set of serum <z:chebi fb="1" ids="17650">cortisol</z:chebi> measurements by request of experienced clinicians </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> paediatric IBD patients receiving conventional doses of oral <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> should be subjected to screening for <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> when anticipated discontinuation of the drug </plain></SENT>
</text></document>